Results 351 to 360 of about 399,014 (392)
Some of the next articles are maybe not open access.
Inhibitors of HIV- I reverse transcriptase
2000Publisher Summary This chapter discusses the current clinically used reverse transcriptase (RT) inhibitors and some promising new inhibitors still in preclinical development, emphasizing the mechanisms of action of RT inhibitors and the mechanisms of viral resistance that develop upon continued exposure of the virus to these compounds.
Nicolas Sluis-Cremer, Michael A. Parniak
openaire +2 more sources
Emtricitabine: A novel nucleoside reverse transcriptase inhibitor
Drugs of Today, 2005Emtricitabine is a once-daily nucleoside reverse transcriptase inhibitor (NRTI) that selectively and potently inhibits human immunodeficiency virus type 1 (HIV-1) replication. Emtricitabine is used in combination with other antiviral agents for the treatment of HIV-1 and is currently under investigation for the treatment of hepatitis B virus (HBV ...
Jean-Michel Molina, Sandra L. Cox
openaire +2 more sources
Chemical Society Reviews, 2012
The human immunodeficiency virus (HIV) causes AIDS (acquired immune deficiency syndrome), a disease in which the immune system progressively deteriorates, making sufferers vulnerable to all manner of opportunistic infections.
C. Reynolds +4 more
semanticscholar +1 more source
The human immunodeficiency virus (HIV) causes AIDS (acquired immune deficiency syndrome), a disease in which the immune system progressively deteriorates, making sufferers vulnerable to all manner of opportunistic infections.
C. Reynolds +4 more
semanticscholar +1 more source
Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors
Environmental and Molecular Mutagenesis, 2007AbstractNucleoside analogs were first approved by the U.S. Food and Drug Administration for use against HIV‐AIDS in 1987. Since then, these agents, now commonly referred to as nucleoside reverse transcriptase inhibitors (NRTIs), have become essential components of the Highly Active Antiretroviral Therapy (HAART) drug combinations used for treatment of ...
openaire +2 more sources
Clinical uses of non-nucleoside reverse transcriptase inhibitors
Reviews in Medical Virology, 2000Three non-nucleoside reverse transcriptase inhibitors (NNRTIs) are currently available for treatment of HIV-1 as part of combination antiretroviral therapy. Oral dosing is administered three times daily for delavirdine (DLV), twice daily for nevirapine (NVP), and once daily for efavirenz (EFV).
Julio S. G. Montaner +2 more
openaire +3 more sources
Novel HIV-1 reverse transcriptase inhibitors
Virus Research, 2008HIV-1 reverse transcriptase (RT) was the first viral enzyme to be targeted by anti-HIV drugs. Despite 20 years of experience with RT inhibitors, new ways to inhibit this target and address viral resistance continue to emerge. In both licensed RT inhibitor classes, nucleosides (NRTIs) and non-nucleosides (NNRTIs), compounds with better resistance ...
openaire +3 more sources
Recent discoveries in HIV-1 reverse transcriptase inhibitors.
Current opinion in pharmacology (Print), 2020Shuang‐Xi Gu +6 more
semanticscholar +1 more source
Current Opinion in HIV and AIDS, 2007
Antiretroviral regimens that combine nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors have consistently been the most effective regimens for the initial treatment of HIV-1 infection. Such combinations have been manufactured in several fixed-dose combinations and are the most commonly used treatments ...
openaire +3 more sources
Antiretroviral regimens that combine nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors have consistently been the most effective regimens for the initial treatment of HIV-1 infection. Such combinations have been manufactured in several fixed-dose combinations and are the most commonly used treatments ...
openaire +3 more sources
Use of nonnucleoside reverse-transcriptase inhibitors
American Journal of Health-System Pharmacy, 1998Christopher D. Holtzer +1 more
openaire +2 more sources
New Reverse Transcriptase Inhibitors in Development
2007Since the identification of HIV as the etiological agent of AIDS, the HIV reverse transcriptase (RT) enzyme has been considered an ideal selective antiretroviral drug (ARV) target. Although several polymerases are found in human cells, none are comparable to HIV RT in their ability to catalyze the synthesis of new DNA from an RNA template.
openaire +2 more sources